Laser-assisted Topical Corticosteroid Delivery versus Intralesional Steroid Injection for Hypertrophic Scars and Keloids: A Meta-analysis
In brief
Laser-assisted steroids cut skin atrophy odds by 95% versus injections
Across eight studies involving 517 patients, laser-assisted corticosteroid delivery slightly improved scar scores and was linked to lower odds of skin atrophy and hyperpigmentation than steroid injections. Pain, satisfaction, and scar recurrence did not differ significantly between treatments, so larger studies are needed to clarify how meaningful the scar improvement is and who benefits most.
- Journal
- Aesthetic plastic surgery (Q1)
- Published
- 12 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Shi-Xin He, Hai-Lun He, Li Yang, Yan Zheng
- PMID
- 43020920
- DOI
- 10.1007/s00266-026-06419-5
Why clinicians should know about it
- Picked for Plastic and Reconstructive Surgery (top studies of the week, 15 November 2026): Comparative scar and keloid treatment outcomes and safety
Abstract
BACKGROUND: Hypertrophic scars (HTS) and keloids are pathological responses to dermal injury that frequently lead to cosmetic disfigurement and functional limitations. Intralesional corticosteroid injection (ISI) is a commonly used treatment but is often associated with pain and local adverse effects. Laser-assisted topical corticosteroid delivery has emerged as a less invasive alternative. This meta-analysis aims to compare the efficacy and safety of these two treatment modalities. METHODS: A systematic literature search was conducted in PubMed, Embase, Cochrane Library, and Scopus up to March 2026. Eligible studies included randomized controlled trials (RCTs) and cohort studies comparing laser-assisted corticosteroid delivery with ISI for the treatment of HTS or keloids. The primary outcome was measured using the Vancouver Scar Scale (VSS). Secondary outcomes included pain scores assessed by the visual analog scale (VAS), patient satisfaction, and the incidence of adverse events. Analyses were performed using Review Manager 5.3. RESULTS: Eight studies involving 517 patients were included. The VSS scores in the laser-assisted corticosteroid delivery group were significantly lower than those in the ISI group (MD = - 0.19, 95% CI: - 0.33 to - 0.05, P = 0.009), suggesting that laser-assisted corticosteroid delivery is more effective. Laser-assisted drug delivery showed a trend toward lower pain scores (MD = - 2.42, 95% CI: - 4.94 to - 0.10, P = 0.06) and showed a non-significant trend toward higher patient satisfaction (OR = 2.32, 95% CI: 0.72 to 7.40, P = 0.16). Regarding safety outcomes, laser-assisted corticosteroid delivery significantly reduced the incidence of hyperpigmentation (OR = 0.33, 95% CI: 0.12-0.92, P = 0.03) and skin atrophy (OR = 0.05, 95% CI: 0.01-0.28, P = 0.0006) compared with ISI group, whereas scar recurrence rates were comparable between the two treatment modalities (OR = 0.66, 95% CI: 0.29-1.52, P = 0.33). CONCLUSION: Laser-assisted corticosteroid delivery demonstrated favorable efficacy in improving scar severity and reducing the incidence of selected adverse events, particularly hyperpigmentation and skin atrophy, compared with ISI group. No significant differences were observed in pain scores, patient satisfaction, or scar recurrence. Given its minimally invasive nature and favorable safety profile, laser-assisted corticosteroid delivery may serve as a promising alternative treatment option for hypertrophic scars and keloids. PROSPERO: CRD420251125880, review completed not published. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.